Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target

Figure 3

Clinical stage analysis of UBE2C. The high UBE2C expression level meant a terminal clinical stage in ACC (a), HNSC (b), KICH (c), KIRC (d), KIRP (e), LIHC (f), LUSC (g), and TGCT (h).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)